#crohn's awareness project

[iatrophilosophos]

Socialized medicine in the US is a partial solution to the myriad of problems with western medicine at best.

Western medicine is theoretically speaking the application of the scientific method to the human body, right? So it seeks to isolate "variables" in the name of "objectivity". Another word for variables here is context. And you just can't in a real way separate context from an individual's state of health; something medical professionals are VERY MUCH AWARE OF (see: shit life syndrome for one example) that exists in tension with both the current regiment of distributing healthcare and with the foundational mythos of western medical knowledge formation.

Western medicine is also beholden to the rest of the world. In places in the US where medicaid is actually relatively accessible, for example, you still have shit like racism and sexism and transphobia and ableism impacting care people get. And I understand that like, when people talk about their ideal socialist utopia, there's mechanisms in place that deal with social oppression; but I want you to think about just how big a project uniform care actually existing would be.

So in our current world, another obstacle to Making Medicine That Works is legality, especially re: the drug war. Very useful, known, well-studied substances have documented properties making them extremely useful or potentially useful for a variety of medical treatments (examples: THC for everything from gut stuff to emotional support; LSD for crohns and potentially diabetes; good old opiates and opiate-related-chemicals for chronic pain, some cases of depression and a subset of the experiences often diagnosed as schizophrenia and/or ADHD): but prohibition prevents application or further study (even for chemicals like THC that are legal in some states, if any program that receives federal funding is involved, can't use it! Fun right?). But sure, we can waive that one aside to and say that universal healthcare will also mean a total end to prohibition. That'd be cool!

So now that we've magicked away these problems, we have uniformly available healthcare that's getting better every day because all the social, legal and financial limits on medical exploration have been taken away. What do we have?

Well aside from a system that's gonna die with the rest of industry any time from next year to a few decades from now, still heavily dependent on plastics and factories and worldwide shipping and coerced labor in other countries, we still have a hierarchical structure where prescriptive knowledge is generated by centralized institutions who's abilities and members are dictated by governmental legislation and that inherently cannot see or account for the context of various people's bodies and lives and thus still limits the ability of disabled and mad people to explore/access unapproved/not-yet-approved treatments. But no, we can magic this one away too, obviously in the ideal socialized healthcare, everyone's needs will be accounted for so we'll have decentralized community medical exploration! And we'll use existing holistic healthcare tools and make more to account for individual people's context! And nobody will be subjected to coerced labor or nonconsensual treatment! And we'll find ways of creating medicine that are locally feasible, don't require global industry, and are resilient against climate collapse!

...so we no longer have contemporary western medicine (or civ, for that matter). Cheers!

But wait! There's more! You can live in this brave new world RIGHT NOW! what do you do with ur time, huh? You play video games? I bet you've put a lot of time and effort and skill-building and resource accumulation into it! Maybe you're poor as shit like me and have figured out emulators and pirating or talk to other people who share your interests about how to access them or you're into indie games! That is cool and meaningful! Maybe you like music! Maybe you like fiction! I bet you know a lot of lore/specifics/techniques/etc related to SOMETHING! maybe it's birds! Idk you but I am absolutely positive that there is SOMETHING you know a lot about that you have figured out how to know in a way that's accessible to you and applicable to your life. Maybe it felt easy, maybe it was really hard, maybe you did it because you want to, maybe you did it because you had to, maybe it's a really big topic, maybe it's a small one, maybe you can think of it right this second and maybe you'd have to ask some friends to point it out to you. Whatever it is, whoever you are, YOU HAVE BUILT A KNOWLEDGE SET AND YOU CAN BUILD ANOTHER ONE! You can start learning about the medicine that is applicable to your life right now. Go read the Wikipedia page for some medications you have around! Or for some ingredient in a food nearby you don't know what is! Or one you do know what is! Figure out a question about it! Google that question! Keep googling! Read some studies that come up and then search all the words you don't know and keep looking until you understand them! Look at you you're doing it! Keep going! This is how it starts!

Medicine exists in the same world we do and we can take it for ourselves and make it better!

[healthcaremarketanalysis]

The Expanding Gastrointestinal Products Market: Trends, Challenges, and Future Prospects

The gastrointestinal (GI) products market has witnessed significant growth in recent years, driven by a rise in GI disorders, advancements in treatment options, and increasing awareness of digestive health. This sector encompasses a broad range of products including medications, devices, and supplements, all aimed at addressing digestive health issues. In this blog, we will explore key drivers, recent advancements, and future trends in the GI products market, alongside challenges that impact the sector.

Download PDF Brochure

1. Overview of the Gastrointestinal Products Market

The gastrointestinal products market encompasses treatments for a wide range of digestive disorders, from acid reflux and irritable bowel syndrome (IBS) to inflammatory bowel disease (IBD) and gastrointestinal cancers. Key products include:

Pharmaceuticals: Anti-inflammatory drugs, antacids, proton pump inhibitors (PPIs), and other medications for symptom management.

Medical Devices: Endoscopes, stents, and other devices for diagnostic and therapeutic interventions.

Nutritional Products and Probiotics: Supplements and specialized diets to promote digestive health and prevent issues.

As digestive disorders become more prevalent globally, the demand for GI products continues to grow. Factors such as poor dietary habits, increasing stress levels, and a rise in obesity have led to a surge in conditions like acid reflux, IBS, and gastrointestinal infections.

2. Market Drivers for Gastrointestinal Products

Several factors are driving the growth of the GI products market:

a) Rising Prevalence of Digestive Disorders

The incidence of digestive issues such as gastroesophageal reflux disease (GERD), Crohn's disease, and IBS is on the rise. According to the World Gastroenterology Organization, approximately 10-15% of the global population suffers from IBS, while GERD affects nearly 20% of people in Western countries. This growing patient pool drives the demand for effective GI products.

b) Aging Population

The global aging population is more susceptible to gastrointestinal issues, from constipation to severe inflammatory disorders. With the elderly population projected to reach 1.5 billion by 2050, the demand for GI products catering to age-related conditions is expected to increase.

c) Advancements in Diagnostic Technologies

New diagnostic tools, such as advanced endoscopy, capsule endoscopy, and improved imaging technologies, have revolutionized how GI diseases are detected and managed. These advancements have enabled earlier and more accurate diagnosis, driving the adoption of gastrointestinal treatments.

d) Lifestyle-Related Factors

Poor dietary habits, sedentary lifestyles, and high levels of stress are associated with digestive disorders. The growing awareness of these lifestyle impacts and their relationship with GI health has increased consumer interest in GI products, especially preventive options like probiotics and fiber supplements.

3. Key Segments in the Gastrointestinal Products Market

The GI products market is diverse, with several key segments:

a) Prescription Medications

Prescription GI medications include anti-inflammatories, PPIs, H2 blockers, and antibiotics. Proton pump inhibitors, in particular, have witnessed strong demand as a treatment for GERD. Despite controversies surrounding long-term PPI use, these drugs continue to be widely prescribed due to their efficacy in reducing acid production.

b) Over-the-Counter (OTC) Medications

OTC medications, including antacids, laxatives, and anti-diarrheal drugs, remain popular for immediate relief from common symptoms. Consumer-friendly products such as chewable tablets and liquid antacids have expanded this segment’s reach, catering to individuals seeking quick, accessible treatments.

c) Medical Devices

The medical devices segment includes endoscopic equipment, capsule endoscopes, and stents. Endoscopy procedures are critical in diagnosing and treating various GI disorders, including ulcers and polyps. Capsule endoscopy, a relatively recent technology, allows patients to ingest a small capsule with a camera, providing minimally invasive diagnostic capabilities.

d) Nutritional Supplements and Probiotics

Increasingly, people are turning to nutritional supplements and probiotics to support their digestive health. Probiotics, in particular, have gained attention for their role in promoting a healthy gut microbiome, which is linked to improved immunity and overall wellness. This segment of the GI market has expanded rapidly, driven by growing consumer awareness of gut health.

Request Sample Pages

4. Recent Advancements in the Gastrointestinal Products Market

The GI products market has seen numerous advancements that improve diagnostic accuracy and treatment efficacy:

a) Biologic Therapies

Biologics have become a cornerstone in the treatment of inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. These therapies target specific molecules involved in inflammation, providing more effective treatment with fewer side effects. Companies are also exploring biosimilars, which offer similar therapeutic benefits as biologics but at a lower cost, making them more accessible.

b) Minimally Invasive Endoscopy

New technologies in endoscopy, such as high-definition imaging and robotics, have transformed the way GI disorders are diagnosed and treated. Minimally invasive techniques reduce patient discomfort and recovery time while providing accurate diagnostic capabilities. Robotic-assisted endoscopy, for example, allows for more precise control and visualization during procedures.

c) Personalized Medicine

Genetic profiling and biomarker research are paving the way for personalized medicine in gastroenterology. By understanding the unique genetic makeup and biomarkers of patients, doctors can provide tailored treatments that maximize efficacy and minimize side effects.

d) Microbiome Research and Probiotics

Research into the human gut microbiome has highlighted its role in GI health and the immune system. This has led to a rise in probiotics and prebiotics aimed at improving gut health by balancing gut bacteria. Ongoing research continues to explore the potential of manipulating the microbiome to treat GI disorders.

5. Challenges in the Gastrointestinal Products Market

Despite its growth, the GI products market faces certain challenges:

a) High Cost of Treatment

Advanced therapies, especially biologics, come with high price tags. This limits access for patients, particularly in low-income regions. Although biosimilars offer a cost-effective alternative, their adoption is still in its infancy due to regulatory hurdles and physician familiarity.

b) Regulatory Hurdles

Stringent regulatory standards apply to new drug and medical device approvals. GI products must undergo extensive testing and trials to ensure safety and efficacy. This slows the time to market for innovative treatments, particularly in regions with rigorous regulatory bodies.

c) Side Effects and Safety Concerns

Many GI medications, such as PPIs, are associated with potential long-term side effects, leading to concerns among patients and healthcare providers. Balancing efficacy with patient safety remains a challenge, driving the need for safer, more effective alternatives.

d) Limited Patient Awareness

Despite rising prevalence, GI disorders often remain underdiagnosed due to a lack of awareness. Many people with symptoms such as heartburn, bloating, or irregular bowel movements may not seek medical help, contributing to a lower diagnosis rate for conditions like IBS and GERD.

6. Future Trends in the Gastrointestinal Products Market

Looking ahead, several trends are likely to shape the GI products market:

a) Growth of Telemedicine in GI Care

Telemedicine has gained momentum, allowing patients to access GI specialists remotely. This can improve access to care, especially for individuals in rural or underserved areas. Telemedicine also facilitates better follow-up care, a key component of managing chronic GI conditions.

b) Artificial Intelligence in Diagnostics

AI is poised to enhance diagnostic capabilities in GI care. Machine learning algorithms can analyze endoscopic images to detect abnormalities such as polyps or tumors, aiding in early diagnosis and improving patient outcomes.

c) Focus on Gut Health and Preventive Care

The link between gut health and overall well-being is driving a focus on preventive care, with more people turning to probiotics, prebiotics, and fiber supplements. As research on the microbiome continues to uncover new connections to health, demand for products that support digestive health will likely grow.

d) Expansion of Biologic and Biosimilar Treatments

The availability of biosimilars will likely expand, making biologic treatments more affordable and accessible. This could be transformative for patients with IBD, allowing more individuals to receive effective, long-term treatment.

Conclusion

The gastrointestinal products market is on a growth trajectory, fueled by the rising prevalence of digestive disorders, advancements in diagnostics and treatments, and increased consumer awareness of gut health. As the market continues to evolve, innovations such as biologic therapies, AI-driven diagnostics, and personalized medicine will play key roles in shaping its future. Challenges such as treatment costs and regulatory complexities remain, but the sector is well-positioned for expansion.

With an aging population, lifestyle-related GI issues, and a global shift toward preventive health, the demand for gastrointestinal products is expected to rise. For stakeholders, from healthcare providers to manufacturers, understanding these dynamics will be crucial for navigating the complexities and tapping into the potential of the GI products market.

[stevenwilliam12]

Gonorrhea Market Forecast and Insights: Trends and Treatment Advances to 2032

Gonorrhea, a prevalent sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, remains a critical public health issue worldwide. If left untreated, gonorrhea can lead to severe health complications, including infertility, pelvic inflammatory disease, and an increased risk of HIV. The rising prevalence of antibiotic-resistant strains of gonorrhea has heightened the urgency for effective treatments and spurred the development of new therapeutic options.

Gonorrhea Market Insights

The gonorrhea treatment market is primarily driven by the increasing incidence of infection and heightened awareness regarding STI prevention and management. While traditional antibiotics like ceftriaxone and azithromycin are commonly used to treat gonorrhea, the emergence of antibiotic resistance is compromising their efficacy. This growing resistance has led to significant research and development (R&D) efforts aimed at creating novel treatment strategies, including dual therapy regimens and new classes of antibiotics. Additionally, the rising demand for rapid diagnostic tests to guide appropriate treatment is contributing to market growth, especially in areas with high infection rates.

The gonorrhea treatment market is expected to expand significantly, particularly in North America and Europe, where robust healthcare infrastructures facilitate early diagnosis and intervention. In contrast, emerging markets in Asia-Pacific and Africa are anticipated to experience growth due to increasing STI awareness and improved access to healthcare services.

Key Gonorrhea Companies in the Market

Leading companies in the gonorrhea treatment market include Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, Achilles Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals, and others, all contributing to the development of innovative treatment options.

Gonorrhea Epidemiology

According to the World Health Organization (WHO), gonorrhea affects millions of individuals globally, with over 80 million new cases reported annually. Young adults, particularly those aged 15-24, account for a substantial proportion of these new infections. Gonorrhea is more prevalent in urban areas, with higher rates observed in marginalized communities and among populations with limited access to healthcare. Furthermore, the increasing incidence of antibiotic-resistant gonorrhea strains poses a significant challenge to effective treatment strategies.

Gonorrhea Market Forecast to 2032

The gonorrhea market size is projected to grow at a compound annual growth rate (CAGR) of approximately 4-5% through 2032. This growth is driven by increased investments in R&D and the introduction of new therapies designed to target resistant strains. The development of combination therapies, novel antibiotics, and improved diagnostic tools will play a pivotal role in shaping the market landscape. Governments and healthcare organizations are also intensifying efforts to combat gonorrhea through awareness campaigns and funding initiatives for the development of new treatments.

ConclusionIn conclusion, the gonorrhea market outlook through 2032 shows promising growth potential, fueled by the pressing need for effective treatment options in response to rising infection rates, antibiotic resistance, and expanded STI prevention initiatives on a global scale.

Latest Reports

Contraceptive Devices Market | Crohns Disease Cd Market | Cutaneous T-cell Lymphoma Market | Diabetic Neuropathy Market | Ehlers-danlos Syndrome Market | Encephalitis Market | Epidermolysis Bullosa Market | Familial Amyloid Polyneuropathy Market | Healthcare Competitive Benchmarking | Hepatic Encephalopathy Epidemiology Forecast | Hepatitis B Virus Market | Hepatitis D Market | Hereditary Spastic Paraplegias Market | Hpv-induced Cancers Market | Human Papillomavirus Positive Cancer Market | Hyperkalemia Market | Nontuberculous Mycobacteria Infection Market | Post-bariatric Hypoglycemia Market | Postsurgical Pain Market | Primary Progressive Multiple Sclerosis Ppms Market | Surgical Stapling Devices Market | Vascular Access Devices Market | Vascular Dementia Market | Wound Closure Devices Market | Xerostomia Market

[ankitblogs0709]

United States Parenteral Nutrition Market Dynamics: Global Growth and Trends (2023-2032)

The market is projected to grow significantly, with an estimated USD 3,266.23 million by 2030. This growth trajectory reflects a Compound Annual Growth Rate (CAGR) of 6.66% from 2023 to 2030.

Parenteral nutrition in the United States is a critical medical treatment for patients who cannot obtain adequate nutrition through traditional oral or enteral feeding methods. This method involves delivering essential nutrients, such as carbohydrates, proteins, fats, vitamins, and minerals, directly into the bloodstream through an intravenous (IV) line. Parenteral nutrition is commonly used in hospitals for patients with severe gastrointestinal disorders, such as Crohn’s disease, short bowel syndrome, or cancer-related malnutrition, as well as for those recovering from surgery or experiencing prolonged periods of intensive care. The United States has established stringent guidelines and protocols for the preparation, administration, and monitoring of parenteral nutrition to ensure patient safety and prevent complications, such as infections or metabolic imbalances. Moreover, advancements in parenteral nutrition formulations and delivery systems have improved patient outcomes and quality of life, making it an essential aspect of comprehensive care in both hospital and home settings.

Key findings from recent studies on the United States parenteral nutrition market reveal several important trends and factors influencing its growth and development:

1. Growing Demand Due to Chronic Illnesses

The rising prevalence of chronic illnesses, such as cancer, gastrointestinal disorders, and malabsorption syndromes, is driving demand for parenteral nutrition. These conditions often prevent patients from obtaining adequate nutrition through regular dietary means, making parenteral nutrition essential.

2. Increasing Use in Home Care Settings

There is a significant shift toward home-based parenteral nutrition as more patients prefer recovery in familiar environments and healthcare providers aim to reduce hospital stays. Improved portable delivery systems and advancements in telehealth are facilitating the safe administration of parenteral nutrition at home.

3. Advances in Formulation and Delivery Systems

Recent innovations in nutrient formulations and delivery systems, such as all-in-one bags and multi-chamber bags, are making parenteral nutrition easier to administer and more efficient. These advancements help reduce the risk of contamination and improve patient outcomes.

4. Rising Awareness and Adoption in Pediatric Care

There is increased awareness of the importance of specialized parenteral nutrition for pediatric patients, particularly newborns with conditions like necrotizing enterocolitis and congenital anomalies. As a result, the market for pediatric-specific parenteral nutrition products is expanding.

5. Stringent Regulatory Requirements

The United States Food and Drug Administration (FDA) and other regulatory bodies have implemented strict guidelines for the preparation, storage, and administration of parenteral nutrition. Compliance with these regulations ensures high standards of patient safety but can also impact market dynamics due to costs associated with regulatory compliance.

6. Cost Considerations and Reimbursement Challenges

While parenteral nutrition can be costly, reimbursement policies by insurance companies and government programs like Medicare and Medicaid significantly impact access. Variations in coverage and reimbursement rates continue to influence the market, with ongoing efforts to improve insurance support for this essential therapy.

7. Growing Focus on Patient Safety and Risk Reduction

Studies highlight the importance of minimizing risks associated with parenteral nutrition, such as infection, liver complications, and metabolic imbalances. As a result, healthcare providers are increasingly investing in staff training and using technology to monitor patients closely, enhancing safety and reducing complications.

8. Increasing Demand in Surgical and Postoperative Care

Parenteral nutrition is increasingly utilized in postoperative and surgical recovery, particularly for patients undergoing major surgeries that affect the digestive system. This trend is expected to continue as more healthcare providers recognize the role of parenteral nutrition in enhancing recovery times and supporting overall patient health.

9. Emphasis on Customized Nutritional Solutions

Personalized or customized parenteral nutrition solutions are gaining popularity as healthcare providers seek to tailor nutrition to each patient’s specific needs. This approach is especially relevant in cases involving unique nutrient deficiencies or complex medical conditions.

Overall, the U.S. parenteral nutrition market is poised for steady growth, driven by the rising incidence of chronic conditions, advancements in home care capabilities, and an increased focus on patient safety and personalized care. However, cost considerations and regulatory challenges will continue to shape the market’s trajectory.

Access Complete Report - https://www.credenceresearch.com/report/united-states-parenteral-nutrition-market

Major Key Players

Baxter

Otsuka Pharmaceutical Factory, Inc.

B. Braun Melsungen AG

Fresenius SE & Co. KGaA

Grifols S.A

Pfizer, Inc.

Actavis, Inc.

Aculife (Nirlife)

Sichuan Kelun Pharmaceutical Co. Ltd.

Hospira, Inc.

Vifor Pharma

The United States parenteral nutrition market is experiencing several innovative trends that are transforming the industry and enhancing patient care. Key trends include:

1. Development of Multi-Chamber Bags

Multi-chamber bags, which separate macronutrients such as amino acids, lipids, and dextrose, allow for safer and more efficient mixing right before administration. This innovation reduces the risk of contamination, streamlines the preparation process, and provides flexibility to customize nutritional solutions according to patient needs.

2. Advances in Portable and Home-Based Delivery Systems

The increased demand for home-based parenteral nutrition is driving innovations in portable delivery systems. Lightweight, battery-operated pumps enable patients to receive nutrition at home or on the go, promoting greater mobility and independence. These systems often integrate with remote monitoring tools, allowing healthcare providers to track the patient’s condition and adjust treatment as necessary.

3. Remote Monitoring and Telehealth Integration

Telehealth and remote monitoring technologies are becoming integral to parenteral nutrition, particularly for patients receiving home care. These technologies enable real-time monitoring of vital signs and infusion data, allowing healthcare providers to detect and address potential issues promptly. This trend improves patient safety and outcomes while reducing the need for frequent hospital visits.

4. Personalized and Tailored Nutrition Formulations

Precision medicine is influencing parenteral nutrition, with healthcare providers increasingly adopting customized formulations tailored to individual patient needs. This approach considers factors like the patient’s age, weight, underlying medical conditions, and specific nutrient deficiencies, allowing for more effective and targeted nutritional support.

5. Lipid Emulsions with Improved Safety Profiles

Advances in lipid formulations, such as fish oil-based emulsions and soybean-free options, are improving the safety and tolerance of parenteral nutrition. These new lipid emulsions help reduce the risk of complications like liver dysfunction and inflammation, which are often associated with long-term parenteral nutrition use.

6. Automated Compounding Devices and Robots

Automated compounding devices and robotic systems are increasingly used in hospitals and pharmacies to prepare parenteral nutrition solutions with greater accuracy and efficiency. These devices minimize human error, enhance the precision of nutrient measurement, and streamline the preparation process, ultimately improving patient safety.

7. Integration of Smart Infusion Pumps

Smart infusion pumps with advanced software and built-in safety features are gaining traction in the parenteral nutrition market. These pumps can monitor flow rates, detect occlusions, and provide real-time feedback on infusion status. They also integrate with electronic health records (EHR) systems, allowing for seamless data sharing and tracking of patient progress.

8. Focus on Sustainable Packaging Solutions

There is a growing emphasis on sustainable packaging for parenteral nutrition products. Innovations include biodegradable materials and recyclable packaging, which reduce environmental impact. This trend aligns with broader healthcare initiatives focused on sustainability and eco-friendly practices.

9. Use of Data Analytics and Artificial Intelligence (AI)

AI and data analytics are being used to optimize parenteral nutrition regimens by analyzing patient data and identifying trends. These technologies assist healthcare providers in personalizing nutrient combinations and dosing, predicting patient outcomes, and identifying potential risks, thereby improving overall care.

10. Enhanced Emphasis on Patient Education and Support Programs

Innovative educational programs and digital tools are being developed to empower patients and caregivers with the knowledge needed to manage parenteral nutrition effectively at home. Mobile apps, online resources, and interactive tools provide information on best practices, symptom tracking, and troubleshooting, which supports adherence and enhances patient confidence.

These innovative trends are shaping the future of parenteral nutrition in the United States, focusing on improving patient safety, convenience, and personalized care. As technology continues to advance, the parenteral nutrition market will likely see further developments that enhance the quality of life for patients and streamline care processes for providers.

Market Segmentations

By Nutrient Type

Single Dose Amino Acid Solution

Parenteral Lipid Emulsion

Carbohydrates

Trace Elements,

Vitamins & Mineral

Browse the full report –  https://www.credenceresearch.com/report/united-states-parenteral-nutrition-market

Contact Us:

Phone: +91 6232 49 3207

Email: sales@credenceresearch.com

Website: https://www.credenceresearch.com

[credenceresearchdotblog]

The Immunomodulator Market is projected to grow from USD 88579.7 million in 2024 to an estimated USD 148816 million by 2032, with a compound annual growth rate (CAGR) of 6.7% from 2024 to 2032.The immunomodulator market has emerged as a critical component of global healthcare, driven by advancements in biotechnology, increasing incidence of autoimmune diseases, and the rising prevalence of cancer and infectious diseases. Immunomodulators, which regulate or modify the immune system, include immunosuppressants, immunostimulants, and others that either enhance or suppress immune activity. The growing awareness of immune-related disorders, coupled with the rise in biologics and personalized medicine, positions the immunomodulator market as one of the fastest-growing segments in the pharmaceutical industry.

Browse the full report at https://www.credenceresearch.com/report/immunomodulator-market

Market Overview

The global immunomodulator market has witnessed remarkable growth in recent years, with significant advancements in therapies targeting autoimmune diseases, cancer, and chronic inflammatory conditions. According to market reports, the immunomodulator market is expected to grow at a compound annual growth rate (CAGR) of around 5-7% over the next decade. Several factors are driving this growth, including the increasing prevalence of diseases like rheumatoid arthritis, multiple sclerosis, lupus, and psoriasis, where the immune system malfunctions and attacks the body's tissues.

Moreover, immunomodulators have gained traction in oncology. They are used to boost the body's immune response against cancerous cells, which has made a significant impact on cancer treatment approaches. Additionally, the market is expanding in the area of infectious diseases, especially with the development of vaccines and treatments for diseases like COVID-19, HIV, and hepatitis.

Key Drivers of the Immunomodulator Market

1. Rising Prevalence of Autoimmune Diseases Autoimmune diseases have seen a sharp rise over the past few decades, with millions of people worldwide affected by conditions like type 1 diabetes, rheumatoid arthritis, Crohn’s disease, and systemic lupus erythematosus. The complex nature of these diseases often requires long-term treatment with immunomodulators to manage symptoms and prevent flare-ups, which has driven demand for more effective therapies.

2. Increase in Cancer Cases and Immunotherapy Adoption The integration of immunomodulators in cancer therapy, particularly in the form of checkpoint inhibitors and monoclonal antibodies, has revolutionized cancer treatment. Immunotherapy drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have shown great promise in treating cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma. The success of these therapies is driving further research and investment in this sector, increasing the market share of immunomodulators in oncology.

3. Advances in Biotechnology and Biopharmaceuticals The development of biopharmaceuticals has led to the creation of more targeted and effective immunomodulators. Unlike traditional drugs, biologics are derived from living organisms and are designed to mimic or enhance the body's natural immune response. The growing number of biopharmaceutical companies investing in research and development (R&D) of immunomodulators has fostered innovation, leading to novel therapies for hard-to-treat conditions.

4. Increasing Geriatric Population The aging population is another factor contributing to the growth of the immunomodulator market. As people age, their immune systems weaken, making them more susceptible to autoimmune diseases, cancers, and infections. Immunomodulators are increasingly being used to help manage these conditions in elderly populations, which is expected to contribute significantly to market growth.

Challenges and Limitations

Despite the promising growth, the immunomodulator market faces several challenges. One major issue is the high cost of biologic therapies, which can limit access to these treatments, especially in low- and middle-income countries. Additionally, side effects such as increased susceptibility to infections and certain types of cancer can be a concern for long-term users of immunosuppressants.

There is also the challenge of balancing immune suppression with immune enhancement. Suppressing the immune system too much can lead to infections, while overstimulating it may trigger autoimmune diseases. Therefore, finding the right therapeutic window for immunomodulators remains a challenge for healthcare providers and researchers.

Regional Insights

North America holds the largest share of the global immunomodulator market, primarily due to the high prevalence of autoimmune diseases and cancer, as well as the availability of advanced healthcare infrastructure and significant investment in R&D. Europe follows closely, with similar factors driving market growth, including favorable government policies that support biopharmaceutical innovation.

Meanwhile, the Asia-Pacific region is expected to witness the fastest growth, attributed to the rising incidence of chronic diseases, increasing healthcare expenditure, and expanding biopharmaceutical industries in countries like China, Japan, and India. The growing middle class and improved access to healthcare services in these regions are further bolstering market expansion.

Future Outlook

The immunomodulator market is poised for sustained growth as researchers continue to unlock the complexities of the immune system. The ongoing development of new immunotherapies, combined with advancements in personalized medicine and targeted therapies, will likely drive innovation in this sector. Moreover, as healthcare systems around the world continue to prioritize the management of chronic diseases and cancer, the demand for immunomodulators will remain robust.

Key Player Analysis:

Abbott

Amgen Inc.

Biogen

Bristol-Myers Squibb Company

Eli Lilly and Company

Hoffmann-La Roche Ltd

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc

Segmentation:

By Product

Biologics,

Small molecules,

Other emerging therapies.

By Application

Autoimmune diseases,

Cancer,

Infectious diseases,

Others

By Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/immunomodulator-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tamanna31]

Pharmacy Market Dynamics, Top Manufacturers Analysis, Trend And Demand, Forecast To 2030

Pharmacy Industry Overview

The global pharmacy market size was estimated at USD 1.26 trillion in 2023 and is expected to grow at a CAGR of 7.28% from 2024 to 2030.

The growing demand for specialty drugs globally and increasing prescription drug expenditure in developed countries are expected to drive the growth of the market over the forecast period. In addition, the growing prevalence of chronic diseases, majorly due to changes in lifestyle and a rapidly aging population, are supplementing the market growth.

The growing demand for prescription medications is contributing to the industry's growth. As the demand for prescription drugs increases, pharmacies experience a surge in business due to the need for dispensing these medications. According to the National Health Service the current cost of an NHS prescription in England for 2024-2025 is USD 12.65 per item, an increase of USD 0.51 from the previous year. Prescription charges are usually reviewed annually. The cost has increased steadily in recent years, from USD 8.80 in 2015 - 2016 to USD 10.47 in 2024 - 2025.

Gather more insights about the market drivers, restrains and growth of the Pharmacy Market

Moreover, pharmacies are adopting digitalization programs to cater to the growing demand from consumers and provide improved accessibility to patients. For instance, CVS Health introduced a Digital Transformation program to personalize the healthcare experience using artificial intelligence, machine learning, data, and analytics. Moreover, in December 2021, the company entered into a partnership with Microsoft to scale up retail personalization and loyalty programs using advanced machine learning, powered by Azure. Such digitalization and automation strategies are anticipated to drive the growth in the industry during the forecast period.

Based on product type, the prescription segment dominated the pharmacy market with the largest revenue share of 81.5% in 2023. The increasing demand for prescription drugs for therapies, such as diabetes, cardiovascular disease, respiratory diseases, antibiotics, blood disorders, and oncology, is driving the growth of the prescription segment. Furthermore, the rising prevalence of long-term health conditions and the expanding elderly demographic are fueling the need for prescription drugs.

According to the IDF Diabetes Atlas, 537 million adults were suffering from diabetes in 2021 globally. The number of adults suffering from diabetes is estimated to increase to 783 million by 2045. Almost 90% of older adults regularly take at least one prescription drug, with many taking multiple medications to manage chronic conditions. This growing need for prescription drugs, especially among the aging population, is expected to significantly drive the growth of the industry in the coming years.

However, the OTC segment is estimated to witness the fastest growth rate during the forecast period. The high growth is due to better cost savings compared to prescription drugs, consumer empowerment in managing minor ailments, a shift toward preventive healthcare, an expanding product range, consumer awareness & education, and the influence of online sales and e-commerce platforms. In addition, the increasing trend of self-medication and conversion of prescription medicines to OTC medications is expected to contribute to the growth of the segment over the forecast period. For instance, in March 2023, the U.S. FDA approved Narcan (4 mg), a naloxone hydrochloride nasal spray, for OTC use. It is the first-ever naloxone product approved to be used OTC

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

• The global Crohn’s disease therapeutics market size was valued at USD 13.20 billion in 2023 and is projected to grow at a CAGR of 2.7% from 2024 to 2030.

• The global estrogen receptor positive breast cancer treatment market size was estimated at USD 19.8 billion in 2023 and is projected to grow at a CAGR of 7.89% from 2024 to 2030.

Key Pharmacy Company Insights

Companies in the market are implementing diverse strategies such as partnerships, collaborations, mergers & acquisitions, and product development to expand their geographical footprint. CVS Health, Boots Walgreens, Walmart, and Rite Aid Corp. are some major players in the market.

Key Pharmacy Companies:

The following are the leading companies in the pharmacy market. These companies collectively hold the largest market share and dictate industry trends.

CVS Health

Boots Walgreens

Cigna

Walmart

Kroger

Rite Aid Corp.

Lloyd Pharmacy

Well Pharmacy

Humana Pharmacy Solutions

Matsumoto Kiyoshi

Apollo Pharmacy

MedPlusMart.com

Recent Developments

In January 2024, Kroger extended its partnership with Centene Corporation's pharmacy network. This extension aimed to provide patients with increased opportunities to save on essential prescriptions. The agreement ensured continued access to the Kroger Family of Pharmacies for approximately 700,000 Centene members in 2024.

In April 2023, Rite Aid Corp launched a new three Rite Aid Pharmacies in Craigsville, Greenville, and Scottsville, Virginia. This initiative was part of a pilot program aimed at enhancing access to services in “pharmacy deserts” and underserved communities.

In February 2022, Medicure Inc. subsidiary Marley Drug Pharmacy in the U.S. introduced its national direct-to-consumer ePharmacy platform, which allows Americans to purchase FDA-approved medications at reduced prices and receive home delivery across all 50 states.

In January 2021, AmerisourceBergen and Walgreens Boots Alliance established a strategic partnership. AmerisourceBergen acquired Walgreens Boots Alliance's Healthcare Business, allowing Walgreens Boots Alliance to enhance its emphasis on expanding its retail operations. This collaboration involves extending and broadening their commercial agreements.

Order a free sample PDF of the Pharmacy Market Intelligence Study, published by Grand View Research.

[bhushans]

Bridging the Gap: How the Global Prophylactic HIV Drugs Market is Expanding Access to Care

The prophylactic HIV drugs market is witnessing significant expansion, with robust growth projected in the coming decade. In 2023, the market size reached an estimated USD 32,516.1 million, driven by increased investment in HIV research and development, rising drug approvals, and a surge in HIV incidence rates.

According to Future Market Insights, the market is forecasted to expand at a Compound Annual Growth Rate (CAGR) of 4.1% between 2023 and 2033, reaching a valuation of approximately USD 48,822.4 million by 2033. This growth trajectory underscores the critical importance of prophylactic HIV drugs in combating the global HIV/AIDS epidemic.

Request Your Detailed Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-9582

Global sales of HIV prophylaxis drugs are projected to reach a value of about USD30 billion by 2021. Owing to growing awareness of HIV and the rising prevalence of HIV infection worldwide, As for AIDS prevention, between 2022 and 2032, the market for preventative HIV drugs grew at a compound annual growth rate (CAGR) of 4%, reaching USD 40 billion in 2028.

HIV has been a major global cause of death for many years, impacting millions of people. People whose immune systems are compromised by the virus are more susceptible to a range of ailments and cancers. HIV can be controlled even when there isn’t a long-term cure by expanding access to adequate care, diagnosis, medication, and prevention.

Prophylactic HIV Drugs: A Powerful Prevention Tool

Effective management techniques are available for HIV, even though a long-term cure is still unattainable. One of the most important aspects of fighting the virus is expanding access to care, diagnosis, treatment, and prevention services. HIV prevention medications are becoming an essential weapon in the fight against HIV infection. These cutting-edge treatments work especially well at preventing HIV transmission through drug injection and sexual contact.

Focus on Pre-Exposure Prophylaxis (PrEP):

Pre-Exposure Prophylaxis (PrEP), one of the preventive HIV medications, is becoming increasingly popular because of its great effectiveness. The risk of HIV infection from sex and injectable drug use can be considerably decreased with PrEP, according to the Centers for Disease Control and Prevention (CDC), by 74% and 99%, respectively. The extraordinary efficacy of PrEP is spearheading a global movement for its expanded usage.

Market Competition:

Some of the prominent players operating in the global market are-

Gilead Sciences, Inc

Merck Sharp & Dohme Corp.

Merck & Co. Inc.

Mylan NV

Cipla Inc.

Genentech Inc.

Bristol-Myers Squibb Company

Johnson & Johnson Health Care Systems Inc

Pfizer Inc.

GalaxoSmithKline PLC

Notable Developments of the Key Players in the Market

In April 2023, Merck & Co (MRK.N) confirmed that it is going to buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, by picking up a promising experimental treatment for ulcerative colitis and Crohn’s disease and building up its presence in immunology.

In November 2022, Merck, known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, might acquire Imago for US$ 36.00 per share in cash for around total equity value of US$ 1.35 billion.

Key Companies Profiled:

Gilead Sciences, Inc

Merck Sharp & Dohme Corp.

Merck & Co. Inc.

Mylan NV

Cipla Inc.

Genentech Inc.

Bristol-Myers Squibb Company

Johnson & Johnson Health Care Systems Inc

Pfizer Inc.

GalaxoSmithKline PLC

Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey:

By Drug Class:

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)

Integrase Inhibitor

By Distributional Channel:

Hospital Pharmacies

Retail Pharmacies

Mail Order Pharmacies

Drug Stores

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

The Middle East and Africa

[health-views-updates]

Inflammatory Bowel Disease Drugs Market 2024 | Outlook, Growth By Top Companies, Regions, Types, Applications, Drivers, Trends & Forecasts by 2031

The global Inflammatory Bowel Disease drugs market has witnessed significant growth in recent years, with a trajectory set to continue upward. Valued at USD 20.55 billion in 2022, it is projected to reach USD 26.85 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period from 2023 to 2030. This growth is fueled by several key factors, including emerging trends, evolving treatment landscapes, and expanding opportunities in the healthcare sector.

Emerging Trends and Opportunities:

Biologics Dominance: Biologic therapies have revolutionized the treatment of IBD, offering targeted approaches with fewer side effects compared to traditional medications. The increasing adoption of biologics, alongside the development of biosimilars, is a notable trend driving market growth.

Personalized Medicine: Advancements in genetics and molecular diagnostics have paved the way for personalized treatment approaches in IBD. Tailoring therapies based on individual patient characteristics, such as genetic markers and disease severity, is gaining traction, leading to more effective and targeted interventions.

Novel Drug Development: Pharmaceutical companies are investing heavily in research and development to bring forth innovative therapies for IBD. From small molecule inhibitors to novel biologics targeting specific pathways implicated in the disease, the pipeline for new treatments is robust, offering promising opportunities for market expansion.

Telemedicine and Digital Health: The COVID-19 pandemic accelerated the adoption of telemedicine and digital health solutions in healthcare delivery. For patients with IBD, remote monitoring, teleconsultations, and mobile health apps offer convenience and improved access to care, presenting a growing market segment for digital health solutions in IBD management.

Download Free Sample Report: https://www.snsinsider.com/sample-request/2988

Key Drivers Propelling Growth:

Rising Disease Prevalence: The prevalence of IBD, including Crohn's disease and ulcerative colitis, is increasing globally, particularly in developed regions. This demographic trend, coupled with better disease awareness and diagnosis, is driving the demand for IBD drugs.

Healthcare Infrastructure Development: Emerging economies are witnessing rapid development in healthcare infrastructure, including increased healthcare spending, improved access to advanced therapies, and enhanced medical facilities. This expansion of healthcare infrastructure creates a conducive environment for market growth.

Regulatory Support and Market Access: Regulatory agencies are streamlining approval processes for IBD drugs, expediting market entry for new treatments. Moreover, initiatives aimed at ensuring affordable access to essential medicines are facilitating market penetration and adoption, especially in emerging markets.

Challenges and Considerations:

High Treatment Costs: The cost of biologic therapies for IBD remains substantial, posing challenges for affordability and access, particularly in resource-constrained settings. Addressing pricing pressures and ensuring equitable access to innovative therapies are imperative for sustainable market growth.

Safety and Efficacy Concerns: While biologic therapies offer significant clinical benefits, concerns regarding long-term safety and efficacy persist. Continued surveillance and post-market monitoring are essential to mitigate risks and ensure the optimal use of IBD drugs.

Patent Expirations and Biosimilar Competition: The impending patent expirations of key biologic drugs in the IBD market will pave the way for biosimilar competition, potentially leading to pricing pressures and market fragmentation. Pharmaceutical companies must navigate this landscape strategically to maintain market share and competitiveness.

Key Takeaways from the Market:

Biologic therapies are driving significant growth in the IBD drugs market, supported by advancements in personalized medicine and novel drug development.

Digital health solutions and telemedicine are reshaping IBD management, offering opportunities for improved patient care and engagement.

Addressing affordability and access challenges, along with ensuring the safety and efficacy of IBD drugs, are critical considerations for sustainable market growth.

Regulatory support, healthcare infrastructure development, and rising disease prevalence are key drivers propelling market expansion, particularly in emerging economies.

In conclusion, the Inflammatory Bowel Disease drugs market is poised for continued growth, driven by emerging trends, evolving treatment paradigms, and expanding opportunities in the healthcare sector. However, addressing challenges related to affordability, safety, and access will be crucial in realizing the full potential of this dynamic market.

[pharmanucleus1]

Global Short Bowel Syndrome Market: Pioneering Treatments and Promising Innovations

Short Bowel Syndrome Market is Expected to Grow at Exponential Pace During Forecast Period of 2022-2027 

Short Bowel Syndrome (SBS) is a group of problems related to poor absorption of nutrients. The main cause of SBS is surgery to remove a portion of the small intestine. This surgery can treat intestinal diseases, injuries, and birth defects. Some people are born with an abnormally short small intestine, significant damage, and poor motility, which can cause short bowel syndrome. Presently, there is no cure for SBS and the treatment is targeted toward symptoms. In a few cases, SBS can be life-threatening but usually, the disease can be managed through effective medication. 

Market Size & Growth Rate: 

The SBS market was valued at USD 1.24 billion in 2021 and is expected to reach USD 4.42 billion by 2027, and is projected to expand at a CAGR of 15.9% during the forecast period 2022-2027. Due to significant research & development, innovative medicines, extensive research, disease prevalence, and favorable reimbursement scenario are anticipated to propel the global short bowel syndrome market. 

Click here for full report:

https://www.pharmanucleus.com/reports/short-bowel-syndrome

Market Dynamics: 

The high cost of parenteral nutrition, favorable reimbursement policies, and increased awareness programs enhanced by various associations like the association of gastrointestinal motility, oley foundations, aspen (clinical nutrition), and the SBS therapeutic project along with increasing government healthcare investments are to project the market growth over the forecast period. 

According to Crohn’s & Coiltis Foundation, SBS affects about three out of every million people each year and approximately 10,000–20,000 people in the United States have short bowel syndrome. Moreover, doctors may remove the small intestine as part of various treatments for Crohn's disease, cancer, and damage from cancer treatment like radiation therapy.                                                                              

In addition, according to WHO-2022, colon & rectum cancers are one of the leading causes of death worldwide, accounting for nearly 1.93 million cases and 916 000 deaths around the globe, these numbers are expected to stimulate the demand for short bowel syndrome medicines through 2027. 

Click here for full report:

https://www.pharmanucleus.com/reports/short-bowel-syndrome

Market Drivers: 

Click here for free ample request:

https://www.pharmanucleus.com/request-sample/1169

Challenges: 

Competitive Landscape: 

Takeda Pharmaceutical Company Limited (Japan), VectivBio AG, 9 Meters Biopharma, Zealand Pharma (Denmark), Hikma Pharmaceuticals (U.K.), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), GSK Plc. (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Merck KGaA (Germany), Swedish Orphan Biovitrum (Switzerland), OxThera, Mylan (US), AstraZeneca (UK), and Others. 

[ananya5400]

Lactase Market Projected to Garner Significant Revenues by 2027

The global lactase market is projected to reach USD 336 million by 2027, at a CAGR of 6.3%, in terms of value, between 2022 and 2027. It is estimated to be valued at USD 247 million in 2022. Lactose is a type of sugar found in milk and other dairy products, lactase is an enzyme that helps in breaking down the milk sugar lactose into simple sugars, namely glucose and galactose. Factors, such as increasing demand for lactose-free and rising product development & innovations in other application areas like pharmaceutical, dietary supplements, and infant nutrition are expected to boost the demand for lactase on a global level. Key players in the market are introducing new food products like lactose-free cream, ice cream, and milk alternatives to address the growing lactase-deficient population.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=125332780

Drivers: Growing lactose intolerance in infants and adults

The development of primary lactose intolerance is temporary and found in premature infants before their small intestine is fully developed. Secondary intolerance is seen in adults when they have a digestive issue in the small intestine. Secondary lactose intolerance is triggered by conditions such as Crohn’s disease or gastroenteritis. According to the National Center for Biotechnology Information (NCBI), nearly 65% of the global population is prone to lactase deficiency. Thus, this has led to an increase in the production of lactose-free dairy products, which helps the lactose-intolerant population to avoid gastrointestinal problems.

Restraints: Rising preference for dairy-free alternatives and vegan diets

The major requirements by consumers recently have been the need for dairy alternatives for removing the problems of cow milk allergy, calorie concerns, lactose intolerance, and the prevalence of hypercholesterolemia. There are other factors such as price, taste exploration, and environmental concerns due to which the shift is seen. Plant-based products are cheaper as compared to meat and dairy products. The manufacturing of lactose-free products is on the higher side due to the usage of the enzyme. Dairy alternatives and vegan products offer different ingredients, tastes, and textures to consumers.

By application, the food & beverages segment is estimated to occupy the largest market share in terms of value

By application, the food & beverages segment is estimated to occupy the largest market share in the lactase market. The lactase enzyme is an enzyme that some people are unable to produce in their small intestines. Without it, lactase-deficient people cannot break down the natural disaccharide in milk. Adding lactase to milk hydrolyzes the lactose naturally found in milk, leaving it slightly sweet but digestible. This property of the enzyme increases its wider application in the food & beverages industry.

Asia Pacific is projected to grow with the highest CAGR in the lactase market during the forecast period

The Asia Pacific region is projected to grow at the highest CAGR during the forecast period and occupies a significant share in the global lactase market. The increasing awareness regarding lactose intolerance in both adults and infants is gaining momentum in the region. Additionally, the demand for lactose-reduced infant formula and lactose-free products for adult nutrition is significantly catering to the growth of the lactase market in the region. Asia Pacific is also witnessing significant expansion in terms of production by key players operating in the market. The regional manufacturers are currently focusing on new product developments and strategic deals such as partnerships, collaborations, and expansions to create more awareness among consumers and cater to the growing demand.

Make an Inquiry @ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=125332780

Key Market Players:

Key players in this market include CHR. Hansen Holdings A/S (Denmark), Kerry Group plc. (Ireland), Koninklijke DSM N.V. (the Netherlands), Novozymes A/S (Denmark), Merck KGaA (Denmark), IFF (US), Amano Enzyme (Japan), Advanced Enzyme Technologies (India), Novact Corporation (US), Antozyme Biotech Pvt. Ltd (India), Nature Biosciences Pvt. Ltd (India), Aumgene Biosciences (India), Creative Enzymes (US), Biolaxi Enzymes Pvt. Ltd (India), Enzyme Biosciences Pvt. Ltd (India), Infinita Biotech (India), Mitushi Biopharma (India), Oenon Holdings Inc. (Japan), Ultreze Enzymes (India), and Senson (Finland)

[crohnsawarenessproject]

‘One Ring’ August 16th, 2022 #onering © Outhouse Cartoons/C.A.P 2022

Last week the day we’ve been waiting for all year finally came to be. My surgery wasn’t supposed to be until September/October but two weeks ago, I was woken by a call from my surgeon telling me that I’d been scheduled right away. At first, I was rather freaked out. We had all these plans to throw my pre-ileostomy body a going away party but the disappointment of fallen plans quickly changed into the hopes for a better life. We immediately hit the ground running. Within a day we were out to see my new Ostomy nurse while getting pre-op bloodwork done. The nurse ran us through a bunch of the basics of life with a bag, giving us a general idea of what was to come. He even sent us home with some sample bags.

I wanted to really get a feel for what I was in for, so I decided to wear one of the bags for 48hrs. Through the day and through the night, I even went and ran errands with it. It was a good primer but not quite the same. It was an empty bag that could only partially simulate what my ileostomy would be like but it was enough to stop some worries. My wife and I also made sure to do a lot of research, choosing not to let others tell us ALL the ins and outs. This made it easier to come up with questions to ask at my first post-op appointment. For the rest of the week my wife would treat me to every craving I could think of! You name it, pizza (artisan), carnitas, steak, ice cream; if I wanted it, she got it for me.

When Tuesday came, I was as prepared as I was ever going to be going through the second major surgery of my life. As these things tend to be, my surgery was bumped by about an hour and a half. Someone in need of an emergency surgery jumped ahead of me but that was okay. I just had to stay out of my head, at that point, alone in the pre-op waiting room. At least they let you keep your phone with you so I was in constant contact with my wife up until the last moment. Once in the OR room the surgeons joked that it was a crowded affair. I was getting a lot of work done with two surgeons working on me simultaneously. I had some laughs with the lovely staff before they put me under and before long I was awake with my new buddy, Shawn. My stoma.

Those who follow me may remember that I call my guts, Gus, after a character in one of my favourite shows called Psych. So I thought it only fitting to name my stoma, Shawn, his partner in crime from the show. Now Shawn & Gus are back together, friends for life.

The first night was decently rough but honestly, I think it wasn’t anything like my first resection. I was off of the button morphine within 24hrs and stopped hydromorphone within 56hrs. I was out of the hospital and back home on day 4. I was up on my feet walking around the house the next day. Another day later I made it out of the house for a quick spell. My energy levels have been growing and it’s been getting much easier to walk & stand up straight. A lot of people were rather surprised with this and, to be honest, I was one of them. But it all came down to the fact that this time around I was the lucky guy who ended up with one of the leading surgeons in the province for non-invasive surgical techniques. They actually pulled all of my colon out through my rectum, having only two laparoscopic points of entry on my stomach. One atop my stoma, the other inside my belly button. It’s really the barbie butt that is causing me to slow down and make sure to not over do it.

My speedier recovery can also be attributed to my amazing wife. Helping to make sure I have what I need but also making sure that I don’t push myself too hard as I tend to do. I’m not a fan of being looked after, so it takes a lot of strength and willpower to not just do everything myself. It’s because of this that I know I will get through this stage without many issues. We are a team and I wouldn’t have it any other way.

Have you had IBD/Ostomy surgery? How did it go for you? What were your experiences? Tell us in the comments below.

[joshua-beeking]

Celebrate Disability Pride Month by learning how to be a better ally featuring Minuamu from Dirge for Broken Men on #WEBTOONCANVAS!

I made a little project with @webtoon on Twitter and Instagram !

(go give a like/RT on their account if you can!)

It was a tremendous amount of fun to make and everyone has been so sweet when planning this! A very big thank you to them for this opportunity!

[FULL TRANSCRIPT BELOW]

How to be a Disability Ally! Special Edition: Autoimmune Conditions by @joshua-beeking

The information found on this post is for educational purposes only, & is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment.

What is an autoimmune disease?

It occurs when a dysfunctional immune system mistakes the body's own cells for harmful invaders. It produces cells & antibodies that attack, & damage healthy cells, tissues, & organs.

This results in a wide spectrum of possible symptoms & severity. There are 80-100 known autoimmune diseases & many more conditions are autoimmune-related. Some autoimmune diseases are organ-specific while others are systemic.

Source: http://autoimmuneinstitute.org

A lot of these conditions are what you would call "Invisible." Their symptoms are often internal & not visible from the outside. Two examples are Crohn's Disease & Rheumatoid Arthritis!

"My creators have these conditions!" - Minamu, Dirge for Broken Men

Possible symptoms of Crohn's Disease include: fatigue, severe diarrhea or constipation, fever, weight loss, malnutrition, abdominal pain, rectal bleeding/blood in stool, mouth sores, anemia, Inflammation of the skin, eyes, joints, liver or bile ducts, kidney stones, delayed physical/sexual development.

Possible symptoms of Rheumatoid Arthritis include: fatigue, joint pain, morning stiffness, swelling of the joints, weight loss, fever, weakness, anemia, inflammation of the skin, eyes, lungs, heart or nerves loss of appetite, periodontitis, local osteoporosis.

It's worth noting that someone can have multiple autoimmune diseases at the same time!

Conditions that affect the digestive tract - Crohn's Disease, ulcerative colitis, or irritable bowel syndrome are often seen as the "black sheep" of awareness coverage for their "embarrassing symptoms."

This causes these conditions to receive poor coverage, support, & understanding caused by social stigmas. Being a better ally starts with gathering information. If a family member or a friend has an autoimmune condition, do your research! Learn as much about it as you can!

You can start to gain a better scope about how that illness affects their daily life. Not only will this help make you more prepared, it'll also help this person be more at ease around you w/out them feeling like they have to share things about their illness they'd rather not.

A lot of people with chronic illnesses are afraid to talk about their condition, or admit that they're in pain for fear of shame or feeling like they're "Bringing down the mood." Please refrain from giving unsolicited advice regarding the medical management of their illness.

Not only is most 'alternative medicine' not scientifically proven & their sources dubious at best, some can prove to be potentially dangerous mixed with other medications or lead to a sudden worsening of the condition or "Flare up."

The people dealing with those illnesses know what's best for them. Another important aspect of autoimmune diseases is symptoms management. Most autoimmune conditions have no definitive cure.

The goal of medical treatment is to reduce symptoms, manage inflammation, maintain remission and improve long-term prognosis by limiting complications.

Keep in mind that no single treatment works for everyone and a lot of people dealing with these conditions have met individuals with "Good intentions" forcefully advising them on how they should manage their illness.

[behaviour to avoid listed below]

[x] "If you were more positive the symptoms would improve!"

[x] "You just aren't trying hard enough to get better."

[x] "But you were fine yesterday!"

[x] "I had stomach pain yesterday and you don't see me cancelling plans for it."

Becoming a better ally means knowing such conditions aren't easy to deal with for the sufferer.

When planning an event, look up bathroom placement for friend with digestive ad and ask what diet restrictions they have.

For ad with movement impairment, plan outings with easy access, mobility assistance or rest areas.

Offer a helping hand with chores or an ear on days when symptoms flare up.

...However! Don't assume someone who appears to be struggling wants the help! Ask before assisting! Being a better ally also means not getting annoyed or angry when your assistance is refused.

While the intention is of course appreciated, some prefer their independence. The loss of autonomy is difficult to accept, and imposing help can be seen as pushy or selfish. In summary: the best thing you can do as an ally is listen, learn, and be understanding of our condition!

Enjoyed this? Take a look at @joshua-beeking webcomic "Dirge for broken men" available on WEBTOON!

You can also support the project on Patreon!

http://Patreon.Com/joshuabeeking

[outhouse-cartoons]

Participating in a gaming marathon to raise money for Crohns research.  Also contributing some promo art...these are the participants as Overwatch characters. And here's how you can donate and learn more about the event!https://fundraise.ccfa.org/campaign/gaming4guts/c148725

[overthinkingbialien]

Happy Birthday Sacha Dhawan (May 1, 1984)

It's May 1st today, which means it's this guy's birthday! This guy who is a phenomenal, hard-working actor, the kind that surprises his employers with a poem he wrote or by asking for a full biography of his character to better work on it, paints his roles on a blank canvas in his head like an artist (his words, not mine) and is loved by everyone on set and beyond. This kind warrior who always speaks up and raises awareness about things that matter, from life with Crohn's Disease and anxiety, to cultural identity, the importance of mental health and systemic racial inequality. And this cutie who's so adorable you wanna cry, I mean, look at him. The little tap dancer who did Michael Jackson impressions has grown up to be the Master and he's damn good at it. I can't wait to see what new projects he's gonna dive into. Happy birthday king, it's so easy to be your fan!

"You're not on your own. Reach out, put it out in the universe, you'd be amazed who takes your hand on the other end." - Sacha Dhawan

[credenceresearchdotblog]

The Gastrointestinal Agents Market is projected to grow from USD 59,863.47 million in 2023 to USD 92,867.89 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.00%.The gastrointestinal (GI) agents market is a rapidly growing sector within the global pharmaceutical industry, driven by the increasing prevalence of gastrointestinal disorders, advancements in drug development, and rising awareness about digestive health. This article explores the key trends, market drivers, challenges, and future outlook of the gastrointestinal agents market.

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

Overview of the Gastrointestinal Agents Market

Gastrointestinal agents are medications used to treat disorders of the digestive system, including conditions like gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), peptic ulcers, Crohn's disease, and ulcerative colitis. These agents are categorized into several classes, such as antacids, proton pump inhibitors (PPIs), H2 receptor antagonists, laxatives, antidiarrheals, and antiemetics. The global gastrointestinal agents market has witnessed significant growth due to the rising incidence of these disorders, coupled with lifestyle changes, aging populations, and increasing adoption of unhealthy diets.

Key Market Drivers

1. Rising Prevalence of Gastrointestinal Disorders: The increasing incidence of GI disorders is a major driver of the market. According to the World Gastroenterology Organization, gastrointestinal diseases affect millions of people worldwide, with a particularly high prevalence in developed countries due to sedentary lifestyles, poor diet, and high levels of stress.

2. Aging Population: The growing aging population is another critical factor contributing to market growth. Older adults are more susceptible to gastrointestinal issues due to age-related changes in the digestive system, making them a key demographic for GI agents.

3. Advancements in Drug Development: Ongoing research and development activities have led to the introduction of novel GI agents that offer improved efficacy and safety profiles. Biologics and targeted therapies, for example, are gaining traction in the treatment of inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis.

4. Increased Awareness and Diagnosis: Enhanced awareness about digestive health and the availability of advanced diagnostic tools have resulted in the early detection and treatment of GI disorders, further boosting the demand for gastrointestinal agents.

5. Rising Healthcare Expenditure: Increased healthcare spending, particularly in emerging economies, has improved access to healthcare services and medications, propelling the growth of the GI agents market.

Challenges Facing the Market

1. Side Effects and Safety Concerns: Many gastrointestinal agents, especially long-term treatments such as PPIs, have been associated with side effects like kidney issues, infections, and bone fractures. Safety concerns can lead to regulatory restrictions and affect market growth.

2. High Cost of Advanced Therapies: The cost of new biologics and targeted therapies can be prohibitive for patients and healthcare systems, particularly in low- and middle-income countries. This cost barrier may limit market expansion in some regions.

3. Generic Competition: The expiration of patents for several blockbuster drugs has led to the entry of generic versions, which, while increasing accessibility, have also intensified competition and put pressure on market prices.

Future Outlook and Opportunities

The gastrointestinal agents market is poised for continued growth, with several opportunities on the horizon:

1. Innovation in Drug Delivery Systems: Innovations in drug delivery systems, such as delayed-release formulations, are expected to enhance the effectiveness of GI agents and improve patient compliance.

2. Personalized Medicine: The development of personalized medicine approaches, where treatment is tailored based on genetic and environmental factors, is gaining momentum. This approach promises to optimize treatment outcomes for GI disorders, particularly IBD.

3. Expansion in Emerging Markets: Emerging markets, including Asia-Pacific and Latin America, offer significant growth opportunities due to improving healthcare infrastructure, increasing disposable incomes, and growing awareness about GI disorders.

4. Digital Health and Remote Monitoring: The integration of digital health technologies and remote monitoring solutions is expected to improve the management of chronic GI conditions, enabling better patient outcomes and driving the demand for GI agents.

Key Player Analysis

Johnson & Johnson

Pfizer Inc.

AstraZeneca

AbbVie Inc.

Takeda Pharmaceuticals

Bayer AG

GlaxoSmithKline plc.

Sanofi

Allergan

Boehringer Ingelheim

Segments:

Based on Type:

Dietary Supplements

Drugs

Antacids

Anti-diarrheal Agents

Anti-emetics

H2 Blockers

Laxatives

Proton Pump Inhibitors

Based on Disease Type:

Constipation

Diarrhoea

Gastroesophageal Reflux Disease

Inflammatory Bowel Disease

Peptic Ulcer Disease

Based on Route of Administration:

Oral

Parenteral

Rectal

Based on End-User:

Homecare

Hospitals & Clinics

Based on Distribution Channel:

Offline Pharmacies

Online Pharmacies

 Based on the Geography:

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/gastrointestinal-agents-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[kieralouiseb]

Young Carers. Hiding In Plain Sight.

[Original post written and published on January 12, 2017]

(Picture: Taken in June 2016 at my last Young Carers Festival)

Well, today I want to talk about Young Carers. Young Carers are everywhere, hence the title of this post. Young Carer's Awareness Day is on the 26th of January this year, which made me post this. If you'd like to know more about #YCAD then please take a look at this link: https://carers.org/young-carers-awareness-day.

I wrote this piece originally with the intention that it was used for fundraising in a church for Young Carers. They were fundraising so that they could pass the money on to the Young Carer Project, under The Children's Society, in the form of gift vouchers. I thought it was a lovely cause and wrote a piece on my experiences as a Young Carer to help pull on the heartstrings and get them donating. So here it is. Please keep an open mind when reading this. If you have any questions to do with this topic I am very open to answering them.

Please reach out via social media or through my email (found on About page).

What is a Young Carer? A ‘Young Carer' is a child who helps look after an immediate family member (mother, father, sibling) who is sick, disabled, has mental health issues, or is misusing drugs or alcohol. These children can be as young as 9 years old. The average age range of a Young Carer is 9 to 18 years old and the average age of Young Carers in the UK in 2016 is 12 years old.

A Young Carer can have multiple different responsibilities and it varies from each family. They could be as simple as cooking, cleaning, and fetching the shopping to offering personal care, emotional support, and providing nursing for the family member.

The aim of the Young Carer project is so that the carers receive support from adults and other children. With adult responsibilities, most children miss out on opportunities to be a child. Growing up as a Young Carer can be isolating, many struggle academically and are vulnerable to bullying. In some cases, there is no relief for the pressures they face at home, and most fear asking for help due to the fear of letting down family or being taken into social care.

There are many carer groups across the UK that aim to support over 200,000 carers who are caring for more than 50 hours per week. Carers are offered emotional support through groups across the country.

My name is Kiera and I cared for my mother who has a diagnosis of Crohn's Disease, Fibromyalgia, and she suffered from mental health issues and alcoholism. My mum was quite capable of doing mundane things for herself like washing and getting dressed, however, I have three younger siblings who all need her attention also. Her illness did not allow her to have much energy which is where I came in. I helped cook, clean and assist her with my younger sisters. I took them to school and picked them up, dressed them, bathed them, fed them, and babysat them.

I went to a group for 13-year-olds and above for 5 years where I met two of my best friends and managed to get my first part-time job. The group I went to was held every week on a Wednesday afternoon after school. It was accessible for children whose parents could not drive and there was a service that could drop us home after the group if needed. Each week there would either be a planned activity such as trampolining or archery or we could have a free “chill out” night where we could listen to music, play pool or watch a film. There was also a dinner option each week as some carers would not be fed at home. I found the group extremely useful as it was a safe place to talk about issues I had or just somewhere quiet to do my homework. It was particularly useful during my exam periods for GCSE and A-Levels.

Each year there is also a Young Carer Festival (YCF) on the last weekend of June from Friday to Sunday. This festival aims to give the carers a three-day rest bite from their caring duties and time for them to just enjoy being children. There are children as young as 8 years to 18 years that all gather from all over the UK to Botley, Southampton at Fairthorne Manor. I went to YCF 4 times during my 5 years with the Young Carers Project and I loved it every year. There are activities for every age group ranging from arts and crafts to musical performances and sporting events. During the day, there are a range of activities for anyone to join, for example, canoeing, rock climbing, abseiling, model clay making, painting, karaoke, football tournaments, or my personal favourite Jacob’s ladder. Then each evening had its own event. On Friday evenings, there was always the Opening Ceremony and then fireworks. On Saturday evening, there was a silent disco. At the silent disco, everyone would wear headphones and two DJs would battle it out between channels to win over the kids with their favourite songs. Going to this festival was one of the highlights of my year as it was a time where I didn’t need to think about my responsibilities and I could just let loose for a weekend with my friends.

Being a Young Carer has benefited me in many ways. I am a more independent and capable individual because I learned how to cook for myself, clean a house, and do other household responsibilities. I began to understand the importance of money and how to pay bills from watching and helping my mum. Now that I am an adult I understand how to fend for myself and look after others. It has made me a more caring and compassionate person and I can provide adequate emotional support for others. However, being a Young Carer has also hindered me in a few ways. Caring for my mum made me feel isolated from other children due to not having the same opportunities as them, I felt alone and I was bullied from age 11 to 14 years old. Whilst going through my GCSE exam period and also my A-Level exam period I had to keep up with my caring responsibilities which gave me less time to revise and learn compared to my non-caring classmates. This contributed to my underachieving in my GCSEs. I have also faced some mental health issues as I had to grow up extremely quickly, I was a lot more mature than some of my classmates at a rather young age.

But I would not change my situation for the world, being a carer has made me interact with many different types of people and learn about different family setups. Being a Young Carer in the UK is difficult though as the projects are slowly disappearing due to funding. But the projects that are still running are better than ever and I just hope that in the future every carer is able to find a group that can help them throughout their childhood and helps them move on to be an adult once the time comes.

You can donate to the Carers Trust here - https://www.donate.carers.org/

By donating, you are helping an amazing cause and helping some of the strongest children in the UK.

Please follow the link for more information on Young Carers in the UK - https://carers.org/young-carers-action-day-2021/young-carers-action-day-2021

That's it. Again, if you made it to the end and you have any questions, please don't hesitate to ask them.